NLRP3 and muscular atrophy: Surprisingly, several drugs targeting the downstream of NLRP3 have conducted clinical trials for certain diseases, and to our knowledge, these drugs have not been investigated for the treatment of sepsis-related skeletal muscle atrophy yet.